Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

Vaccinating pregnant women against RSV reduced the risk of infection in their infants by 61% compared with newborns with ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...

Pfizer said it will 'support capacity-building initiatives, such as training healthcare professionals and advancing clinical ...

Expectant mothers will have access to free vaccines against respiratory syncytial virus (RSV) from next month under a major ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

According to CDC researchers, cases of tularemia in the U.S. increased by nearly 60% from 2011 to 2022 compared with the ...

Nearly 80% of infants born in a California health system were exposed to nirsevimab or the maternal respiratory syncytial ...

In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...